Efficacy of daratumumab (Dara) retreatment using a histone deacetylase-inhibitor (HDACi: panobinostat) as a Dara-longevity-inducing, epigenetic agent in combination with bortezomib-dexamethasone as a quadruplet in relapsed / refractory multiple myeloma (RRMM) patients
Latest Information Update: 26 Dec 2022
At a glance
- Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Panobinostat (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms Dara-H-VERUMM
- 25 Dec 2022 Status changed from recruiting to discontinued.
- 25 Mar 2021 New trial record